Astec LifeSciences Limited (ASTEC.NS)
- Previous Close
656.60 - Open
649.05 - Bid --
- Ask --
- Day's Range
634.60 - 660.00 - 52 Week Range
634.60 - 1,474.40 - Volume
17,188 - Avg. Volume
40,162 - Market Cap (intraday)
12.742B - Beta (5Y Monthly) 0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-68.68 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 21, 2023
- 1y Target Est
845.00
Astec LifeSciences Limited, together with its subsidiaries, engages in the manufacture and sale of agrochemical active ingredients and pharmaceutical intermediates in India. It offers triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maize, as well as grains, such as barley, rice, and wheat; post-harvest drench; and food additive and wood preservative. The company also provides herbicides, insecticides, and specialty chemical products. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.
www.godrejastec.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: ASTEC.NS
View MorePerformance Overview: ASTEC.NS
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASTEC.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASTEC.NS
View MoreValuation Measures
Market Cap
12.88B
Enterprise Value
18.39B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.38
Price/Book (mrq)
5.49
Enterprise Value/Revenue
4.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-35.34%
Return on Assets (ttm)
-7.40%
Return on Equity (ttm)
-44.57%
Revenue (ttm)
3.81B
Net Income Avi to Common (ttm)
-1.35B
Diluted EPS (ttm)
-68.68
Balance Sheet and Cash Flow
Total Cash (mrq)
27.05M
Total Debt/Equity (mrq)
235.96%
Levered Free Cash Flow (ttm)
-212.17M